Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The deal adds vaccine candidates for respiratory syncytial virus and human metapneumovirus to the French pharmaceutical group ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Human metapneumovirus doesn’t account for all the unknown viruses, but it’s a significant proportion – about as many cases as RSV or influenza. But no one knows about it.

The Centers for Disease Control and Prevention said human metapneumovirus – also known as HMPV – filled intensive care units with children and seniors this spring.

This spring has been kind of a meta experience. This isn’t referring to the owner of Facebook. No, there’s been a surge of the human metapneumovirus (HMPV). In fact, in mid-March, at the ...

Vermont has the second lowest state fatality rate in the US (148.5 per 100K; Hawaii 113.8/100K). Mississippi (466.2/100K) and Oklahoma (461.5/100K) have the highest rates. The US average is 308.2/100K ...

"Human metapneumovirus doesn't account for all the unknown viruses, but it's a significant proportion — about as many cases as RSV or influenza." So a person may have had the disease without ...

Human metapneumovirus is a respiratory virus that mainly infects children, the elderly, and people with compromised immune systems. It frequently resembles symptoms of the typical cold or flu ...

Read: Cases of human metapneumovirus surge; What are the signs, symptoms of HMPV? 3. Just like RSV and the flu, HMPV can cause people to be admitted to intensive care units and can cause deadly ...

Officials in India have confirmed the country's first seven cases of human metapneumovirus, or HMPV, which is reportedly surging in neighboring China. Jan 7 ...